{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T09:30:28Z","timestamp":1775986228615,"version":"3.50.1"},"reference-count":25,"publisher":"American Chemical Society (ACS)","issue":"13","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Org. Chem."],"published-print":{"date-parts":[[2024,7,5]]},"DOI":"10.1021\/acs.joc.4c00399","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:51:32Z","timestamp":1718905892000},"page":"9313-9321","source":"Crossref","is-referenced-by-count":2,"title":["Enantioselective Synthesis of \u03b2-<scp>l<\/scp>-5-[(<i>E<\/i>)-2-Bromovinyl)-1-((2<i>S<\/i>,4<i>S<\/i>)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) Uracil)] (<scp>l<\/scp>-BHDU) <i>via<\/i> Chiral Pure <scp>l<\/scp>-Dioxolane"],"prefix":"10.1021","volume":"89","author":[{"given":"Yugandhar","family":"Kothapalli","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia 30602, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-2491","authenticated-orcid":true,"given":"Chung K.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia 30602, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3085-0888","authenticated-orcid":true,"given":"Uma S.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia 30602, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"316","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.16"},{"key":"ref2\/cit2","unstructured":"https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html (accessed April 19, 2024)."},{"issue":"3","key":"ref3\/cit3","first-page":"74","volume":"14","author":"Breuer J.","year":"2007","journal-title":"Herpes"},{"issue":"2","key":"ref4\/cit4","first-page":"95","volume":"41","author":"Freer G.","year":"2018","journal-title":"New Microbiol."},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.274"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1317410"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26041132"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.3390\/v14020192"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.07.039"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1002\/med.20011"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1007\/BF01221032"},{"issue":"8","key":"ref12\/cit12","first-page":"2006","volume":"5","author":"Johnson M. R.","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03338-12"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.07.007"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.13.948190"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00545"},{"key":"ref17\/cit17","unstructured":"Singh, U. S.; Chung, C. K. Prodrugs of l-bhdu and methods of treating viral infections U.S. Patent 20,230,167,143 A1, 2023."},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200040643"},{"key":"ref20\/cit20","unstructured":"Sznaidman, M.; Painter, G. R.; Almond, M. R.; Cleary, D. G.; Pesyan, A. Methods to manufacture 1,3-dioxolane nucleosides. U.S. Patent 20,110,130,559 A1. 2011."},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.09.008"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1021\/jm990543n"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600909578"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ces.2022.117686"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1002\/cber.19811140404"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1021\/ol049714v"}],"container-title":["The Journal of Organic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.joc.4c00399","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.joc.4c00399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T08:19:51Z","timestamp":1720167591000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.joc.4c00399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,5]]}},"alternative-id":["10.1021\/acs.joc.4c00399"],"URL":"https:\/\/doi.org\/10.1021\/acs.joc.4c00399","relation":{},"ISSN":["0022-3263","1520-6904"],"issn-type":[{"value":"0022-3263","type":"print"},{"value":"1520-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}